

West Virginia Medicaid Drug Utilization Review Board Minutes

November 14, 2018

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
Ernest Miller, DO
Kate Forman, PharmD
Michael Ballow, PharmD
Michael Lonsinger, PharmD
C.K. Babcock, PharmD
John Vanin, MD
Myra Chiang, MD
Chris Terpening, PharmD, PhD
Scott Brown, RPh (via phone)
Mary Nemeth-Pyles, MSN, RN, CS (via phone)
Christopher Booth, PharmD (via phone)

Members Absent:

John Guilfoose, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Change Healthcare

I. INTRODUCTIONS

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:06 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM September 26, 2018 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

1. None

IV. NEW BUSINESS

A. Speakers

- | | | |
|---------------------|----------------|----------|
| 1. Sharon Haggerty | US World Meds | Lucemyra |
| 2. Michael Raffaele | Sanofi Genzyme | Dupixent |

B. Updates from the October 24, 2018 Pharmacy & Therapeutics Committee Meeting

1. Dr. Labus and the Board reviewed the updates from the October 24, 2018 P&T meeting. No criteria changes were requested beyond those presented in section IV-C of this document.

C. PDL Prior Authorization Criteria (Attachment A)

1. **Entresto** – Update criteria to reflect an AutoPA checking for age (over 18) and a diagnosis of chronic heart failure.
2. **Mitigare** – Update sub-class criteria to apply to all agents, not just Mitigare.
3. **Tresiba & Fiasp** – Removed from Non-Preferred criteria as both agents will be preferred
4. **Lyrica CAPSULES** – Update sub-class criteria to apply to Non-Preferred Lyrica formulations (CR and Solution only) as Capsules will be preferred.
5. **Flector Patch** – Removed Non-Preferred criteria as agent will now be preferred. Changed quantity limits to maximum dosing of 1 patch per day.
6. **Vimpat** – Removed the AP notation on Vimpat as it no longer applies.
7. **Glucocorticoid/Bronchodilator Combos** – Removed sub-class criteria. This sub-class will now follow the Class PA Criteria.
8. **CGRP** – Approved as presented (See attachment A)
9. **Epidiolex** – Approved as presented (See attachment A)
10. **Dupixent** – Approved with the addition of a requirement for eosinophils of ≥ 150 cells/mcL in asthma of eosinophilic phenotype (per manufacturer recommendation)
11. **Latuda** – Updated criteria to allow for a 30-day trial of EITHER Quetiapine OR a combination of Olanzapine and Fluoxetine, instead of requiring both.
12. **Lucemyra** – The Board recommended updating the presented criteria to remove two items (If being requested for a scheduled withdrawal*, medical justification must be provided to support why an opioid taper cannot be used AND Patient must have documentation of a severe or life-threatening allergy to clonidine (reaction must be described).) The Board also recommended adding a requirement that the patient have a normal QT interval. Criteria was approved on condition these changes were implemented.

V. REPORTS

- A. **Molina Quarterly Report** – Eric Sears presented an overview of the Molina 2018 Third Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.

- B. Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the Third Quarter 2018. (Attachment 3).

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. None

VII. NEXT MEETING AND ADJOURNMENT

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:44 p.m. EDT.
- C. The next meeting will be Wednesday, February 27, 2019 from 4:00 p.m.–6:00 p.m. and located at WVDHHR.